U.S. Markets closed

Vifor Pharma AG (VIFN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
126.50+1.10 (+0.88%)
At close: 5:30PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close125.40
Open125.50
Bid123.00 x 0
Ask126.50 x 0
Day's Range125.50 - 127.45
52 Week Range99.68 - 140.55
Volume190,840
Avg. Volume202,430
Market Cap8.204B
Beta (5Y Monthly)1.24
PE Ratio (TTM)22.89
EPS (TTM)5.53
Earnings DateAug 05, 2021
Forward Dividend & Yield2.00 (1.48%)
Ex-Dividend DateMay 10, 2021
1y Target Est163.00
  • Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
    Business Wire

    Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma

    ST. GALLEN, Switzerland, June 24, 2021--Regulatory News: Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years. Prior to that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management

  • Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
    Business Wire

    Vifor Pharma to revise DIAMOND study, readout expected in H2 2021

    ST. GALLEN, Switzerland, June 24, 2021--Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in potassium management in high-risk heart failure patients treated with guideline-recommended doses of renin-angiotensin aldosterone system inhibitor (RAASi). This decision has been made on the recommendation from the independent study Executive Committee and followi

  • OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
    GlobeNewswire

    OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

    MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). On May 17, 2021, JT notified OPKO of its decision to terminate the exclusive agreement with OPKO’s subsidiary, EirGen Pharma, Ltd., for the development and commercialization of RAYALDEE® in Japan based on a comprehensive review of its development pipeline. Concurrently with the termination of JT’s rights, EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP by including Japan into the existing exclusive agreement between the two companies, executed on May 9, 2016, for the development and commercialization of RAYALDEE® in Europe and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency. About RAYALDEE® RAYALDEE® is an extended release formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the only medicine approved by the U.S. Food and Drug Administration that sufficiently raises serum total 25-hydroxyvitamin D to effectively lower blood levels of intact parathyroid hormone. RAYALDEE® is approved to treat SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in the U.S. and 11 European countries. It is not yet approved for patients with stage 5 CKD on dialysis. About Vifor Fresenius Medical Care Renal Pharma Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care) is part of the Vifor Pharma Group (VPG), a global pharmaceutical company. VPG aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. VPG strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care and holds a leading position in all its core business activities. VPG is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). About OPKO Health, Inc. OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including information about RAYALDEE® and its potential benefits. Risks and uncertainties include, among other things, the uncertainties inherent in VFMCRP’s ability to successfully commercialize RAYALDEE® and the success of our relationship with our commercial partners for RAYALDEE®. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. CONTACTS: LHA Investor Relations Yvonne Briggs, 310-691-7100ybriggs@lhai.comorBruce Voss, 310-691-7100 bvoss@lhai.com